XyloCor plans to use the Extroducer system to administer its gene therapy XC001 directly into the heart without the need for invasive surgical interventions. Image Credit: REDPIXEL.PL / Shutterstock.

XyloCor Therapeutics has signed a licencing agreement with SmartWise, a subunit of SmartCella Holding, to use the latter’s Extroducer infusion catheter system to administer  gene therapies directly into the heart and other hard-to-reach tissues.

XyloCor will pay approximately $130m in upfront and milestone-based payments to SmartCella for the supply of Extroducer for clinical trials and commercial use. SmartCella will also be entitled to ‘mid-single digit’ royalties.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

XyloCor plans to use the Extroducer system to administer its cardiovascular gene therapy XC001 (encoberminogene rezmadenovec). The use of Extroducer system allows for the direct administration of XC001 into the heart without the need for invasive surgical interventions.

XC001 is adenovirus-based gene therapy, which is designed to reduce ischaemic burden by creating new blood vessels in the heart through the local expression of multiple isoforms of vascular endothelial growth factor (VEGF).

The company is investigating the gene therapy as a treatment for refractory angina. In May, XyloCOr reported positive results from the Phase II EXACT trial (NCT04125732). XC001 significantly increased exercise duration and decreased the frequency of angina episodes. Angina class improved in 81% of participants at 6 months.

There were no treatment-related severe adverse events. However, the 20 expected severe adverse events were related to the surgical procedure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We welcome the Extroducer delivery of XC001 as it offers a more efficient method for gene therapy administration for patients with refractory angina,” said Timothy D. Henry MD, Interventional Cardiologist and Director of the Lindner Center, The Christ Hospital, Cincinnati, Ohio.

“Preclinical models provide strong evidence that this approach will maintain, or even improve the efficacy when compared to surgical delivery and it should lower the risk of complications that may arise from surgical administration. I am looking forward to initiating the Phase IIb trial of XC001 in patients with refractory angina using this innovative administration approach.”

Extroducer is designed to allow direct tissue or organ infusions through the vessel wall into organs and tumours. The system was cleared by the US Food and Drug Administration (FDA) to direct organ or tissue transfer in 2022. Last week, SmartCella raised approximately €50m ($54m) to expedite its growth and bolster the commercialisation of Extroducer.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva. 

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.